H. Lundbeck Management

Management criteria checks 4/4

H. Lundbeck's CEO is Charl van Zyl, appointed in Sep 2023, has a tenure of 2.5 years. total yearly compensation is DKK28.50M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 0.009% of the company’s shares, worth $521.79K. The average tenure of the management team and the board of directors is 2.5 years and 4 years respectively.

Key information

Charl van Zyl

Chief executive officer

DKK 28.5m

Total compensation

CEO salary percentage	32.63%
CEO tenure	2.5yrs
CEO ownership	0.009%
Management average tenure	2.5yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Charl van Zyl's remuneration changed compared to H. Lundbeck's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2025	DKK 29m	DKK 9m	DKK 3b
Sep 30 2025	n/a	n/a	DKK 4b
Jun 30 2025	n/a	n/a	DKK 3b
Mar 31 2025	n/a	n/a	DKK 3b
Dec 31 2024	DKK 28m	DKK 9m	DKK 3b
Sep 30 2024	n/a	n/a	DKK 3b
Jun 30 2024	n/a	n/a	DKK 3b
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

Compensation vs Market: Charl's total compensation ($USD4.43M) is below average for companies of similar size in the US market ($USD7.74M).

Compensation vs Earnings: Charl's compensation has been consistent with company performance over the past year.

CEO

Charl van Zyl (58 yo)

2.5yrs

Tenure

DKK 28,500,000

Compensation

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charl van Zyl	President & CEO	2.5yrs	DKK 28.50m	0.0092% $ 521.8k
Joerg Hornstein	CFO & Executive VP of Corporate Functions	3.6yrs	DKK 11.40m	0.010% $ 587.4k
Lars Bang	Executive Vice President of Product Development & Supply	7.2yrs	DKK 10.70m	0.0091% $ 518.4k
Per Luthman	Executive Vice President of Research & Development	7.2yrs	DKK 11.90m	0.022% $ 1.3m
Tarek Samad	Senior VP & Head of Research	4.8yrs	no data	no data
Jens Hoyer	Vice President & Head of Investor Relations	1.2yrs	no data	no data
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	2.2yrs	no data	no data
Dianne Holto	Executive Vice President of People	1.9yrs	no data	0.013% $ 724.2k
Thomas Gibbs	Executive VP & Head of Lundbeck in United States	3.1yrs	no data	no data
Johannes Streffer	Senior VP & Head of Global Clinical Development	no data	no data	no data
Michala Fischer-Hansen	Executive VP and Head of Europe & International Markets and Operations	1.9yrs	no data	0.0023% $ 131.7k
Maria Alfaiate	Executive Vice President of Corporate	1.6yrs	no data	no data

2.5yrs

Average Tenure

53yo

Average Age

Experienced Management: HLBB.F's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lene Skole-Sorensen	Deputy Chair	11.2yrs	DKK 1.28m	0.0062% $ 352.4k
Jeffrey Berkowitz	Independent Director	8yrs	DKK 1.24m	no data
Lars Holmqvist	Director	11.2yrs	DKK 638.00k	0.0076% $ 431.7k
Jakob Riis	Director	3yrs	DKK 638.00k	0.056% $ 3.2m
Lars Green	Independent Director	1yr	DKK 563.00k	no data
Ilse Wenzel	Independent Chair of the Board	5yrs	DKK 1.56m	0.0091% $ 517.8k
Santiago Arroyo	Independent Director	5yrs	DKK 1.14m	no data
Camilla Andersson	Employee Representative Director	4yrs	DKK 438.00k	0.00037% $ 21.1k
Dorte Clausen	Employee Representative Director	4yrs	DKK 438.00k	0.00011% $ 6.3k
Hossein Armandi	Employee Representative Director	4yrs	DKK 438.00k	no data
Lasse Skibsbye	Employee Representative Director	4yrs	DKK 438.00k	0.00026% $ 14.8k

4.0yrs

Average Tenure

59yo

Average Age

Experienced Board: HLBB.F's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/09 16:53
End of Day Share Price	2026/02/24 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 33 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Emily Field	Barclays
Charles Pitman	Barclays
Charles Pitman	Barclays

H. Lundbeck Management

Management criteria checks 4/4

Key information

Recent management updates

H. Lundbeck A/S, Annual General Meeting, Mar 23, 2026

H. Lundbeck A/S, Annual General Meeting, Mar 26, 2025

H. Lundbeck A/S Announces Board Changes

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Recent updates

H. Lundbeck A/S Announces Positive Phase IIb Top-Line Results with Bocunebart (Lu AG09222; Anti-PACAP mAb) in Migraine Prevention

H. Lundbeck A/S to Report Fiscal Year 2026 Results on Feb 03, 2027

H. Lundbeck A/S Proposes Dividend for 2025

H. Lundbeck A/S Announces Six-Month Data from the 12-Month, Real-World Infuse Study

H. Lundbeck A/S Presents Comprehensive New Bexicaserin Dataset Epilepsies

H. Lundbeck A/S Announces the Acceptance of Its New Drug Application

H. Lundbeck A/S (CPSE:HLUN B) submitted a non binding proposal to acquire Avadel Pharmaceuticals plc (NasdaqGM:AVDL) for $ 2.1 billion.

H. Lundbeck A/S, Annual General Meeting, Mar 23, 2026

Lundbeck Announces its Bexicaserin Receives Breakthrough Therapy Designation in China for Treatment of Seizures in Severe Rare Epilepsies

Otsuka and Lundbeck Receives Complete Response Letter from U.S. FDA for sNDA of REXULTI®? (Brexpiprazole) in Combination with Sertraline for the Treatment of Adults with PTSD

H. Lundbeck A/S to Present New Data on Bexicaserin At Upcoming Congress

H. Lundbeck A/S Raises Earnings Guidance for the Full Year 2025

H. Lundbeck A/S Announces New Data from Phase III Trial Confirms Efficacy of Vyepti®? (eptinezumab) in Asian Population with Chronic Migraine

Lundbeck Advances Leadership in Migraine with New Data at American Headache Society 67th Annual Scientific Meeting

H. Lundbeck A/S Raises Earnings Guidance for the Full Year 2025

H. Lundbeck to Share Pipeline Data and Key Insights into the Progression of Rare Disease, Multiple System Atrophy, at International MSA Congress in Boston

H. Lundbeck A/S to Present Positive Pipeline Data At American Academy of Neurology Annual Meeting

H. Lundbeck A/S Expands the Dose Findings to Intravenous Administration of Lu AG09222 in Migraine Prevention

H. Lundbeck A/S Approves to Distribute Dividend for the Year 2024

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S (Lundbeck) Approves Rxulti®? (Brexpiprazole) for the Treatment of Schizophrenia

H. Lundbeck A/S Provides Earnings Guidance for the Year 2025

H. Lundbeck A/S, Annual General Meeting, Mar 26, 2025

H. Lundbeck A/S Announces Board Changes

H. Lundbeck A/S Announces Positive Results from 12-Month Open-Label Extension of the PACIFIC Trial Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

H. Lundbeck A/S (Lundbeck) Announces That the U.S. Food and Drug Administration Plans to Host A Psychopharmacologic Drugs Advisory Committee Meeting to Seek Input on Issues Related to the Supplemental New Drug Application for Brexpiprazole

H. Lundbeck A/S to Report First Half, 2025 Results on Aug 20, 2025

H. Lundbeck A/S Announces Positive Results from the Resolve Trial

H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S to Report Q1, 2023 Results on May 10, 2023